GeneQuine Biotherapeutics is a company.
GeneQuine Biotherapeutics has raised $7.0M across 1 funding round.
Key people at GeneQuine Biotherapeutics.
GeneQuine Biotherapeutics has raised $7.0M in total across 1 funding round.
Key people at GeneQuine Biotherapeutics.
GQ Bio Therapeutics GmbH (formerly GeneQuine Biotherapeutics) is a Germany-based biotechnology company founded in 2012, specializing in gene therapy for chronic musculoskeletal disorders like osteoarthritis and intervertebral disc degeneration.[1][2][3] It develops transformative treatments using its proprietary high-capacity adenoviral vector (HCAd) platform, which enables efficient delivery of large genes, high transduction efficiency, and scalable manufacturing.[2][3] The company's lead products include GQ-501, a HCAd vector expressing proteoglycan 4 (lubricin) and IL-1Ra for osteoarthritis, and GQ-401, targeting intervertebral disc degeneration with an undisclosed protein—both in preclinical stages.[3] With 16 employees, sites in Hamburg, Luckenwalde (near Berlin), and Liège (Belgium), GQ Bio serves large biotech, big pharma, and smaller biotechs via out-licensing, addressing unmet needs in prevalent diseases affecting millions.[2][3]
GQ Bio Therapeutics, originally founded as GeneQuine Biotherapeutics in 2012 (some sources note 2011), emerged from an independent foundation focused on gene therapy for musculoskeletal disorders.[2][3][4] Co-founder and CEO Kilian Guse, an industry veteran, leads the company, which has evolved from early R&D in Hamburg to a sharpened focus on its HCAd platform.[2][3] A pivotal moment came in May 2023 with the name change to GQ Bio Therapeutics, facility expansion to 750 sqm in Luckenwalde for vector production and preclinical work, and Guse's board appointment—signaling readiness for clinical trials.[2] Early traction includes partnerships with Pacira, Exothera, Baylor College of Medicine, and mSKIL, building momentum toward out-licensing its pipeline.[3]
GQ Bio rides the gene therapy boom for musculoskeletal diseases, where traditional treatments fail to modify disease progression amid aging populations and rising osteoarthritis/disc degeneration prevalence.[1][3] Timing aligns with advances in viral vectors post-2023 approvals (e.g., for other indications), favoring scalable platforms like HCAd amid manufacturing bottlenecks plaguing competitors.[2] Market forces include surging demand for one-time therapies in orthopedics—a $10B+ addressable market—and EU funding for German biotech hubs.[1][2] GQ Bio influences the ecosystem by pioneering high-capacity vectors, potentially enabling combo-gene therapies and out-licensing to pharma giants, while its Berlin/Liège expansion bolsters Europe's biotech corridor.[2][3]
GQ Bio is poised for clinical trial entry with GQ-501/GQ-401, leveraging HCAd scalability to attract big pharma partnerships or acquisition—watch for Phase 1 data in 2026-2027.[2][3] Trends like AI-optimized vectors and combo-gene delivery will amplify its edge, while regulatory tailwinds in Europe propel growth amid global musculoskeletal therapy gaps. Its influence may evolve from preclinical innovator to licensed platform leader, transforming chronic disease management much like early gene therapy pioneers reshaped rare diseases—positioning it as a key player in biotech's next wave.[2][3]
GeneQuine Biotherapeutics has raised $7.0M in total across 1 funding round.
GeneQuine Biotherapeutics's investors include Forbion, High-Tech Gründerfonds.
GeneQuine Biotherapeutics has raised $7.0M across 1 funding round. Most recently, it raised $7.0M Series A in February 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2021 | $7.0M Series A | Forbion, High-Tech Gründerfonds |
